Public Good Pharma helps payers and self-insured employers cut through the barriers that keep drug costs high.

Unlike traditional Pharma, PGP is motivated to prove low-cost alternatives, or reduced dosing of specialty drugs can provide equal or better outcomes while reducing your costs.

Public Good Pharma partners with health insurers to design and run self-funding Interventional Pharmacoeconomic (IVPE) trials that compare expensive specialty drugs to lower-cost alternatives, including repurposed generics, biosimilars, dose de-escalations and lifestyle interventions. This model, referred to as a “revolving research fund”, is already being successfully implemented in the Netherlands.

Established as a social enterprise, our long-term objective is supporting adoption of the most cost-effective therapies that improve access and sustainability. We work with forward-thinking payers aligned with improving the affordability of healthcare, including self-insured employers, pass-through PBMs, state health plans, and integrated health systems.

Connect with us to explore how IVPE trials can guarantee 20% cost-savings per patient during IVPE trials with likelihood of 50-90% cost-savings on the most expensive speciality drugs on your health plan, including cell & gene therapies.

Reduce Financial Toxicity

Improve Patient Outcomes

The cost of new patented drugs is unsustainable

user icon

42%

US cancer patients lose all assets

box icon

$300K

Median annual price of new drugs

medicine-pills

3000+

Repurposable generic drugs

Our Team